ArticleFrontiers in pharmacology2026
Isobavachalcone attenuates experimental periodontitis by suppressing PTGS2-associated macrophage ferroptosis and restoring periodontal immune homeostasis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Periodontitis (PD) is a destructive inflammatory disease driven by the collapse of immune homeostasis and alveolar bone resorption. Isobavachalcone (IBC) is a naturally occurring prenylated chalcone belonging to the plant flavonoid family, mainly enriched in the mature seeds of Methods: Experimental periodontitis was induced in rats by ligation combined with Porphyromonas gingivalis LPS topical application. Alveolar bone parameters were analyzed via micro-CT and histology. Network pharmacology, molecular dynamics (MD) simulations, cellular thermal shift assays (CETSA) and microscale thermophoresis (MST) assays were integrated to screen and validate the physical binding targets of IBC. Single-cell RNA sequencing (scRNA-seq) analysis and clinical samples were utilized to confirm translational relevance, and Results: Conclusion: IBC acts as a potent protective agent against periodontitis by directly targeting the PTGS2-MAPK-ROS-GPX4 axis, thereby inhibiting macrophage ferroptosis and restoring periodontal immune homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.